Ukraine has stopped deliveries to Russia is vitally important drug – RIA Novosti

06:02 14.06.2016

(updated: 07:12 14.06.2016 )

24922 3 91

MOSCOW, June 14 -. RIA Novosti Ukrainian manufacturer stopped supplying to the Russian drug Mezaton, which is included in the Russian list of essential drugs, and demanded to increase the purchase price. This writes “Kommersant” on Tuesday with reference to the manufacturer, the drug used by doctors and specialized Russian agencies.

According to the publication, produced Mezaton pilot plant at the Kharkov Scientific Center of medicines. According to the newspaper, the drug is massively used in resuscitation, anesthetists and obstetricians for local and general anesthesia, most often used in case of injuries, wounds, acute circulatory failure.

According to the publication intensivists, anesthesiologists and ambulance staff from several regions, including Moscow, Mezaton either ended, or at the end, “the remnants of last year’s reserves still there, but warned that there will be no new”. According to the newspaper, the Ministry of Health of the Rostov Region has appealed to the Federal Ministry of Health with a request to deliver a drug or to exclude it from the list of vital and essential drugs.

In Roszdravnadzor newspaper confirmed that “at the present time in the Russian market there are shortages Mezaton supply of the drug, which is included in the list of vital and essential medicines. ” According to the ministry, in 2016 the drug were reported in treatment

“However, the Russian market there are similar drugs that are similar in pharmacological effect with mezaton Currently Roszdravnadzor sent a request to the supplier of the next timing of supply of the drug.”. – said the newspaper, the press service of the department.

In Roszdravnadzor added that the reasons for the termination of deliveries are unknown to them. The representative producer Natalia Crow told the newspaper that the price of the drug has not changed in six years. “In 2010, the Russian government has compiled a list of vital and essential drugs, where and Mezaton came in. But since its purchase price has not changed. We are not able to re-register the price of the drug. At the moment, we can simply no longer supply it at the same price – this would mean that we are working at a loss, “- said the publication of the Raven

.